Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directed great attention and anxiety all over the world. Epidemiologic models predict that the current COVID-19 pandemic will last several months or even several years, until the development of a vaccine and/or herd immunity. Although the course of the infection is often not severe in children, it can be life threatening especially in immunocompromised children with leukemia. Hematopoietic and lymphoid cancers are accounting for approximately 40% of all childhood cancers. The five-year survival rate for childhood cancer has approached to 70% and more than 80% for leukemia in our country. During COVID pandemic, children with leukemia may also have COVID-19 infection, especially when their bone marrow is depressed due to chemotherapy. It is observed that factors such as the underlying type of cancer, status of remission, or having stem cell transplantation may affect the prognosis. As well as standard and proven treatments for febrile neutropenia, all tests and treatments should be applied very quickly and properly for COVID 19 as is all suspected patients. These efforts may contribute to increase the survival of our children with cancer. Given the absence of data to address concerns related to SARS-CoV-2 infection while on chemotherapy, questions are increasing about the approach for management of systemic immunosuppressive therapies, i.e. ceasing or reducing the immunosuppressive medications in children with leukemia. The current rapid worldwide spread of COVID-19 necessitates identifying optimal preventive strategies and effective medical management. In this report, we tried to review appropriate literature-based approaches for prevention, diagnosis and management of treatment protocols for children with cancer during the pandemic period.

Keywords: Children, Medical Management, Leukemia, SARS COV-2 Infection

References

  1. World Health Organization (2020) Coronavirus disease (COVID-19) pandemic. (website) https://www.who.int/emergencies/diseases/novel-coronavirusc. (accessed on 29/04/2020)
  2. CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:343-6.
  3. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics 2020;145:e20200702.
  4. Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are childrenless susceptible to COVID-19? J Microbiol Immunol Infect 2020;53:371-2.
  5. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children – United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep 2020;69:422-6.
  6. Wang XF, Yuan J, Zheng YJ, Chen J, Bao YM, Wang YR, et al. Retracted: Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen. Zhonghua Er Ke Za Zhi 2020 ;58(0):E008.
  7. Qiu H,Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis 2020;20:689-96.
  8. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. N Engl J Med 2020;382:1663-5.
  9. Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. Clin Exp Pediatr 2020;63:125-32.
  10. Chen L, Liu M, Zhang Z, Qiao K, Huang T, Chen M, et al. Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease. Br J Ophthalmol 2020;104:748-51.
  11. Hu K, Patel J, Patel BC. Ophthalmic Manifestations Of Coronavirus (COVID-19). 2020 Apr 13. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan.
  12. Recalcati S. Cutaneous manifestations in COVID-19: a firstperspective. J Eur Acad Dermatol Venereol 2020 Apr 21; doi: 10.1111/jdv.16519.
  13. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
  14. Center for Disease Control and Prevention.(website) Information for Healthcare Professionals: COVID-19 and Underlying Conditions https://www.cdc.gov/coronavirus/2019-ncov/hcp/underlying-conditions.html (accessed on 10/05/2020)
  15. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol 2020 Mar25; e200980.
  16. Lewis MA. Between Scylla and Charybdis - Oncologic Decision Making in the Time of Covid-19. N Engl J Med 2020;382:2285-7.
  17. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239–42.
  18. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.Lancet Oncol 2020;21:335-7.
  19. Enserink M, Kupferschmidt K. With COVID-19, modeling takes on life and death importance. Science 2020;367:1414-5.
  20. Türk Pediatrik Hematoloji Derneği. Çocukluk Çağı Kanser Kayıtları. (online) http://www.tphd.org.tr/wp content/uploads/2017/11/Cocukluk_Cagi_Kanser_KayitlariMehmet_Akif_Yesilipek.pdf (erişim tarihi: 08/05/2020)
  21. Ogimi C, Englund JA, Bradford MC, Qin X, Boeckh M, Waghmare A. Characteristics and Outcomes of Coronavirus Infection in Children: The Role of Viral Factors and an Immunocompromised State. J Pediatric Infect Dis Soc 2019;8:21-8.
  22. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020;10:783-91.
  23. Balduzzi A, Brivio E, Rovelli A, Rizzari C, Gasperini S, Melzi ML, et al. Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati. Bone Marrow Transplant 2020 Apr 20;1-6. doi: 10.1038/s41409-020-0895-4.
  24. Sung L, Koh A. Infectious Disease In The Pediatric Cancer Patient. Ch67 Supportive Care.In: Nathan and Oski’s Hematology and Oncology of Infancy and Childhood E-Book 8th ed. Philadelphia, USA: Elsevier Saunders 2014:2257-66.
  25. Hakim H, Flynn P. Complications and Supportive care. Infectious complications in leukemia. Ch 32. In: Ching-Hon Pui (editor). Childhood Leukemias. 3rd ed. pp. Memphis, TN, USA: Cambridge University Press. 2013:772-93.
  26. Okoye AA, Picker LJ. CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev 2013;254:54-64. Kumar D, Humar A. Respiratory viral infections in transplant and oncology patients. Infect Dis Clin North Am 2010;24:395-412. Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi 2019;41:19-28.
  27. Desai A, Sachdeva S, Parekh T, Desai R. COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis. JCO Glob Oncol 2020;6:557-9.
  28. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med 2020;8:e35.
  29. Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, et al. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Virol 2020;127:104371.
  30. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; and the Northwell COVID-19 Research Consortium. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020:323;2052-9.
  31. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020;323:1574–81.
  32. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020 Mar 23. doi: 10.1001/jama.2020.4683.
  33. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335-7.
  34. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia 2020;34:1637-45. Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Do Patients with Cancer Have a Poorer Prognosis of COVID-19? An Experience in New York City. Ann Oncol 2020 Apr 21. pii: S0923-7534(20)39303-0. doi:10.1016/j.annonc.2020.04.006.
  35. Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A,Pradhan K, et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov 2020 May 1. pii: CD-20-0516. doi: 10.1158/2159-8290.CD-20-0516.
  36. Boulad F, Kamboj M, Bouvier N, Mauguen A, Kung AL. COVID-19 in Children With Cancer in New York City. JAMA Oncol 2020 May 13. doi: 10.1001/jamaoncol.2020.2028.
  37. Hrusak O, Kalina T, Wolf J, Balduzzi A, Provenzi M, Rizzari C, et al. Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. Eur J Cancer 2020;132:11-6.
  38. T.C. Sağlık Bakanlığı (2020). COVID-19 Halka Yönelik Sıkça Sorulan Sorular (online). (website) https://covid19bilgi.saglik.gov.tr/tr/sss/halka-yonelik.html (accessed on 10/05/2020).
  39. T.C. Sağlık Bakanlığı (2020). Sağlık Kurumlarında Enfeksiyon Kontrol Önlemleri (online). (website)
  40. https://covid19bilgi.saglik.gov.tr/tr/enfeksiyon-kontrol-onlemleri.html (accessed 10/05/2020).
  41. World Federation for Ultrasound in Medicine and Biology Safety Committee (Jacques S. Abramowicz, Iwaki Akiyama, David Evans, J. Brian Fowlkes, Karel Marsal, Yusef Sayeed and Gail ter Haar), Abramowicz JS, Basseal JM. World Federation for Ultrasound in Medicine and Biology Position Statement: How to Perform a Safe Ultrasound Examination and Clean Equipment in the Context of COVID-19. Ultrasound Med Biol 2020;46:1821-6.
  42. Man RX, Lack DA, Wyatt CE, Murray V. The effect of natural disasters on cancer care: a systematic review. Lancet Oncol 2018;19:e482-9.
  43. Bouffet E, Challinor J, Sullivan M, Biondi A, Rodriguez-Galindo C, Pritchard-Jones K. Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences. Pediatr Blood Cancer 2020 Apr 2:e28327. doi: 10.1002/pbc.28327. [Epub ahead of print] PubMed PMID:32239747.
  44. Ng PC, So KW, Leung TF, Cheng FW, Lyon DJ, Wong W, et al. Infection control for SARS in a tertiary neonatal centre. Arch Dis Child Fetal Neonatal Ed 2003;88:F405-9.
  45. Leung TF, Ng PC, Cheng FW, Lyon DJ, So KW, Hon EK, et al. Infection control for SARS in a tertiary paediatric centre in Hong Kong. J Hosp Infect 2004;56:215-22.
  46. Bin SY, Heo JY, Song MS, Lee J, Kim EH, Park SJ, et al. Environmental Contamination and Viral Shedding in MERS Patients During MERS-CoV Outbreak in South Korea. Clin Infect Dis 2016;62:755-60.
  47. Ecancer. What to expect: Oncology’s response to coronavirus in Italy. (website) https://ecancer.org/en/news/17495-what-to-expect-oncologys-response-to-coronavirus-in-italy (accessed on 15/05/2020)
  48. Sullivan M, Bouffet E, Rodriguez-Galindo C, Luna-Fineman S, Khan MS, Kearns P, et al. The COVID-19 pandemic: A rapid global response for children with cancer from SIOP,COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. Pediatr Blood Cance 2020 May 13:e28409. doi: 10.1002/pbc.28409.
  49. American Society of Clinical Oncology Official Web site: COVID-19 Patient Care Information https://www.asco.org/asco-coronavirus-information/care-individuals-cancer-during-covid-19 (Accessed on 10/05/2020)
  50. UptoDate. Cancer Care During the Pandemic. (website) https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-cancer-care-during-thepandemic? (accessed on 08/05/2020)
  51. Barfield R, Rosoff P, Kodish E. Ethical Considerations in Pediatric Oncology Clinical Trials. Ch 74. In: Stuart H. Orkin, David G. Nathan, David Ginsburg, A. Thomas Look, David E. Fisher, Samuel Lux (editors). 8th ed. Nathan and Oski’s Hematology and Oncology of Infancy and Childhood E-Book. Elsevier Saunders. Philadelphia PA. USA 2015;2467-81.
  52. Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol 2020 ;17:268-70.
  53. Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI. A War on Two Fronts: Cancer Care in the Time of COVID-19. Ann Intern Med 2020;172:756-8.
  54. Segelov E, Underhill C, Prenen H, Karapetis C, Jackson C, Nott L, et al. Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic. JCO Oncol Pract. 2020 May 13:OP2000229. doi: 10.1200/OP.20.00229. [
  55. He Y, Lin Z, Tang D, Yang Y, Wang T, Yang M. Strategic plan for management of COVID-19 in paediatric haematology and oncology departments. Lancet Haematol 2020;7:e359-62.
  56. Percival MM, Lynch RC, Halpern AB, Shadman M, Cassaday RD, Ujjani C, et al. Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy. JCO Oncol Pract 2020 May 5:OP2000241. doi: 10.1200/OP.20.00241.
  57. Yahalom J, Dabaja BS, Ricardi U, Ng A, Mikhaeel NG, Vogelius IR, et al. ILROG Emergency Guidelines for Radiation Therapy of Hematological Malignancies During the COVID-19 Pandemic. Blood 2020;135:1829-32.
  58. Xing YH, Ni W, Wu Q, Li WJ, Li GJ, Wang WD, et al. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019. J Microbiol Immunol Infect 2020;53:473-80.
  59. Ogimi C, Greninger AL, Waghmare AA, Kuypers JM, Shean RC, Xie H, et al. Prolonged Shedding of Human Coronavirus in Hematopoietic Cell Transplant Recipients: Risk Factors and Viral Genome Evolution. J Infect Dis 2017;216:203-9.
  60. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfus Med Rev 2020;34:75-80.
  61. Ali M, Zaid M, Saqib MAN, Ahmed H, Afzal MS. SARS-CoV-2 and the Hidden Carriers - Sewage, Feline, and Blood Transfusion. J Med Virol 2020 Apr 28. doi: 10.1002/jmv.25956.
  62. Corman VM, Rabenau HF, Adams O, Oberle D, Funk MB, Keller-Stanislawski B, et al. SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission. Transfusion 2020 ;60:1119-22.

Copyright and license

Copyright © 2020 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Yazal Erdem A, Özbek NY. SARS COV-2 Infection in Children with Leukemia. Turk J Pediatr Dis [Internet]. 2025 Jul. 24 [cited 2025 Aug. 23];14:41-7. Available from: https://turkjpediatrdis.org/article/view/1208